Journal
GROWTH FACTORS
Volume 32, Issue 2, Pages 74-81Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/08977194.2014.896355
Keywords
Cell surface; erbB2; erbB3; FLIM; FRET; receptor dynamics; therapeutic antibodies
Categories
Funding
- Institute for Advanced Studies
- Israel Science Foundation
- Eli Lilly
- Genentech Inc.
Ask authors/readers for more resources
The epidermal growth factor receptor (EGFR) undergoes a conformational change in response to ligand binding. The ligand-induced changes in cell surface aggregation and mobility have a profound effect on the function of all the family members. Ligand also activates the EGFR intracellular kinase, stimulating proliferation and cell survival. The EGFR family are often activated, overexpressed or mutated in cancer cells and therapeutic drugs (including antibodies) can slow the progress of some cancers. This article provides a brief, annotated summary of the presentations and discussion which occurred at the Epidermal Growth Factor Receptor - Future Directions Conference held in Jerusalem in November 2013.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available